Cannabis Science, Inc. is a biotech company based in Irvine, California. The company was incorporated in 2009 and formerly traded under the ticker CBIS on the Over-The-Counter Bulletin Board until October 2019, when their SEC license was revoked.
The company's stated goal was to obtain Food and Drug Administration (FDA) approval for cannabis-based medicines, with a focus on treating skin cancer (basal and squamous cell carcinomas), posttraumatic stress disorder and HIV. The FDA has not approved these treatments.